Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 8 - K CURRENT REPORT Pursuant to Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 Date of Report ( Date of earliest event reported ) : February 4 , 2021 CORVUS PHARMACEUTICALS , INC . Delaware ( State or other jurisdiction of incorporation ) ( Exact name of registrant as specified in its charter ) 001-37719 ( Commission File Number ) 863 Mitten Road , Suite 102 Burlingame , CA 94010 ( Address of principal executive offices , including Zip Code ) Registrant's telephone number , including area code : ( 650 ) 900-4520 46-4670809 ( IRS Employer Identification Number ) Check the appropriate box below if the Form 8 - K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ㅁㅁㅁㅁ Written communications pursuant to Rule 425 under the Securities Act ( 17 CFR 230.425 ) ☐ Soliciting material pursuant to Rule 14a - 12 under the Exchange Act ( 17 CFR 240.14a - 12 ) Pre - commencement communications pursuant to Rule 14d - 2 ( b ) under the Exchange Act ( 17 CFR 240.14d - 2 ( b ) ) Pre - commencement communications pursuant to Rule 13e - 4 ( c ) under the Exchange Act ( 17 CFR 240.13e - 4 ( c ) ) Securities registered pursuant to Section 12 ( b ) of the Act : Title of each class Common Stock , Par Value $ 0.0001 per share Trading symbol ( s ) CRVS Name of each exchange on which registered Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 17 CFR §230.405 ) or Rule 12b - 2 of the Securities Exchange Act of 1934 ( 17 CFR §240.12b - 2 ) . Emerging growth company ☑ If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . ☑